Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.

Detailed Description
-----------------
OBJECTIVES: Primary Determine intermediate biomarkers of premalignant respiratory epithelial lesions, such as genetic mutations or altered growth factor expression, in patients with dysplasia of the respiratory epithelium or lung cancer, head and neck cancer, or aerodigestive tract cancer. Secondary Establish a tissue repository of normal and dysplastic respiratory epithelium from endobronchial forceps and brush biopsy tissue from these patients and from normal volunteers. OUTLINE: Patients are stratified according to presence of extensive and severe dysplasia of the respiratory epithelium (yes vs no). Participants undergo sputum cytology, white-light (with or without fluorescence) bronchoscopy, and endobronchial biopsies. Participants also undergo endobronchial brushings and bronchial secretion collection and possibly bronchoalveolar lavage. Collected samples are processed by hematoxylin, eosin, and immunohistochemical staining and analyzed for specific biomarkers. Unused samples are stored in the tissue bank. PROJECTED ACCRUAL: A total of 330 participants will be accrued for this study.

Official Title
-----------------
Biomarkers and Dysplastic Respiratory Epithelium

Conditions
-----------------
Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition

Intervention / Treatment
-----------------
* Other: immunohistochemistry staining method
* Other: laboratory biomarker analysis
* Other: sputum cytology
* Procedure: biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Meets any of the following criteria: Diagnosis of extensive and severe dysplasia of the respiratory epithelium Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia) Survived 1 or more aerodigestive system carcinoma for ≥ 1 year Completely resected stage I non-small cell cancer Undergoing any of the following procedures: Routine panendoscopy for patients with head and neck cancer Resection of a bronchogenic carcinoma Bronchoscopy for diagnosis or staging of suspected lung cancer Subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment in patients with prior high-grade dysplasia or worse No asthma No lung disease No respiratory illness within the past 2 weeks Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes. PATIENT CHARACTERISTICS: No clinically apparent bleeding diathesis No known bleeding disorder No anginal No clinically active coronary artery disease No multifocal premature ventricular contractions No poorly controlled congestive heart failure No myocardial infarction within the past 6 weeks No cardiac dysrhythmia that is potentially life threatening Well-controlled atrial fibrillation or rare (< 2/min) premature ventricular contractions allowed No ventricular tachycardia or supraventricular tachycardia with a rapid ventricular response No other serious medical condition that would preclude a patient from undergoing a bronchoscopy No acute bronchitis or pneumonia within the past 8 weeks except when clinically proven as a possible result of lung cancer No hypoxemia (i.e., < 90% saturation with supplemental oxygen) before bronchoscopy PRIOR CONCURRENT THERAPY: See Disease Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: immunohistochemistry staining method|Laboratory test|
|Other: laboratory biomarker analysis|Laboratory Test|
|Other: sputum cytology|Laboratory Test|
|Procedure: biopsy|Laboratory Test|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic mutations or altered growth factor expression |  | After study has completed | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establishment of a tissue repository of normal and dysplastic respiratory epithelium |  | After study has closed | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-small cell lung cancer, small cell lung cancer, squamous lung dysplasia, hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, metastatic squamous neck cancer with occult primary, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus and nasal cavity cancer, salivary gland cancer, esophageal cancer, pulmonary carcinoid tumor, tongue cancer